This study examined the sedative, analgesic, behavioral, and clinical effects of a combination of xylazine (XY) and nalbuphine-xylazine (NA-XY) in camels. A total of five adult camels were used in a prospective randomized cross-over design with a wash out period of two weeks. Camels were allocated randomly to two treatment groups: the XY group (xylazine, 1.1mL/100 kg IV) and the NA-XY group (xylazine, 1.1mL/100 kg IV and nalbuphine, 1 mg/kg IV). The sedative, analgesic, behavioral, and clinical effects of XY and NA-XY combination were evaluated prior to administration (baseline) and at 5, 15, 30, 45, 60, 75, 90, and 120 minutes post-administration. The results showed that the NA-XY combination accelerates the onset of sedation and analgesia and prolongs the durations of both sedation (p < 0.001) and analgesia (p < 0.01). The behavioral parameters showed higher scores with a NA-XY combination than xylazine alone. Although a XY injection resulted in a significant decline in the heart and respiratory rate, the NA-XY combination group revealed a non-significant change in both clinical parameters compared to the baseline. In conclusion, the use of a NA-XY combination in camels improved the sedative and analgesic onset and duration with an improved outcome in the behavioral scores, as well as in both the heart and respiratory rates compared to XY alone.

No abstract

The purposes of this study were to describe the most applicable approach of manus blockade in camel using ultrasound-guided techniques. The study was performed on 40 forelimbs of 20 apparently healthy mature freshly slaughtered camels. Limbs were randomly allocated into 3 phases of the study. Phase-I (n=8 limbs): dissection of both dorsal and palmar aspects to identify the topographical anatomy of the target nerves. Phase-II (n=8 limbs): dissection after US guided needle insertion to confirm the needle insertion position. Phase-III (n=24 limbs): US-guided methylene blue injection using one of three volumes (3, 5, or 7 mL) to establish the ideal injection volume. Our results revealed that the dorsal aspect of manus received its innervation from dorsal common digital nerves II and III (DCDN-II & III) and dorsal common digital nerve IV (DCDN-IV). The palmar aspect of manus was received its innervation from the palmar common digital nerve IV (PCDN-IV) and the median nerve. Under Ultrasonographic guidance, the most applicable approach for blocking the DCDN-II & III is at the dorsomedial aspect at about 8-10 c.m below the carpometacarpal joint (CMJ) and 2 cm medial to CDET. Blocking of the DCDN-IV is performed at the dorsolateral aspect at about 8-10 c.m below the CMJ and 2 cm lateral to CDET. Blocking the PCDN IV was performed at the lateral and palmar aspect at about 10-12 c.m below the accessory carpal bone (ACB) and 5 cm palmar to the imaginary line bisect the forelimb longitudinally from lateral to medial. Blocking the median nerve was performed at the proximal third of medial and palmar aspect of metacarpal bone at about 10-12 c.m below the ACB and about 5 cm palmar to the same imaginary line. In conclusion, four point blockade of the manus region in dromedary cadavers can be achieved by US-guided injection of the DCDN-II, III, DCDN-IV, PCDN-IV, and the median nerve.